Abbott has reported new data from its Volt CE Mark Study in individuals treated with PFA therapy using the Volt PFA System ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Johnson & Johnson MedTech announced positive three-month results from a study evaluating its investigational Omnypulse ...

Abbott (NYSE: ABT) today announced new study data demonstrating the safety and efficacy of its Volt pulsed field ablation ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt™ ...

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced positive, initial 3-month results from the Omny-IRE study, evaluating the investigational OMNYPULSEtm ...

Notably, no serious adverse events were reported, and no complications were linked to the platform, including zero neurovascular events or coronary spasms. Among a subset of 115 patients treated ...

The first chest pain hit Heather Bardeleben as she pored over a spreadsheet while working late into the evening at her ...

A discussion of a challenging case of renal artery denervation for resistant hypertension. Hypertension (HTN) is estimated to ...